We have located links that may give you full text access.
[Treatment of irritable colon syndrome with rociverine].
Minerva Medica 1993 May
Forty outpatients of both sexes suffering from irritable colon syndrome were treated for four weeks with rociverine, an antispastic agent with anti-muscarinic and direct miolytic activities, at a dose of 20 mg x 3. The aim of the study was to assess the efficacy and tolerability of this dose since the drug is normally administered at a dose of 30-40 mg a day. The efficacy of treatment was assessed on the basis of the evolution of clinical symptoms, whereas its tolerability was evaluated in both clinical and biohumoral terms. The results of the study showed that a dose of 60 mg/die of causes a marked and significant reduction of the typical symptoms of irritable colon, in particular abdominal pain, with no variation in analytical findings and a small number of clinically unimportant side effects.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app